Products
Ipragliflozin is not currently registered in many countries. It was first approved in Japan in 2014 (Suglat).
Structure and properties
Ipragliflozin (C21H21FO5S, Mr = 404.5 g/mol) is a benzthiophene derivative.
Effects
Ipragliflozin has antidiabetic and antihyperglycemic properties. It is a selective inhibitor of sodium–glucose co-transporter 2 (SGLT2). This transporter is responsible for the reabsorption of glucose at the proximal tubule of the nephron. Inhibition leads to increased excretion of the sugar via the urine. The mechanism of action is independent of insulin, unlike other antidiabetic agents. Ipragliflozin is specific for SGLT2 and does not inhibit SGLT1, which is responsible for glucose absorption in the intestine.
Indications
For the treatment of type 2 diabetes.
